AlloMap molecular expression testing: Difference between revisions

Revision as of 19:41, 21 September 2017

Revision as of 20:31, 21 September 2017

Line 1:

{{db-promo|this is medical marketing, not a Wikipedia article. Would have to be completely rewritten. [[User:Jytdog|Jytdog]] ([[User talk:Jytdog|talk]]) 19:40, 21 September 2017 (UTC)}}

'''AlloMap molecular expression testing''', developed and commercialized by CareDx, formerly known as XDx, is a gene expression profiling test to identify [[heart transplantation|heart transplant]] recipients with a low probability of one type of [[organ transplant|transplant]] rejection. The test is performed on a [[blood]] sample, providing a non-invasive test to help manage the care of patients post transplant. Prior to the availability of this test, the primary method for managing heart [[transplant rejection]] was the invasive technique of endomyocardial biopsy.<ref>{{cite web | last=Thomlison | first=B | title=Success With AlloMap Molecular Expression Testing | publisher=Medical News Today | date=2007-05-12 | url=http://www.medicalnewstoday.com/articles/70268.php }}</ref>